Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.
Front Immunol. 2022 Aug 15;13:946422. doi: 10.3389/fimmu.2022.946422. eCollection 2022.
Extracellular vesicles (EVs) are membrane-bound particles released by cells in various (patho)physiological conditions. EVs can transfer effector molecules and elicit potent responses in recipient cells, making them attractive therapeutic agents and drug delivery platforms. In contrast to their tremendous potential, only a few EV-based therapies and drug delivery have been approved for clinical use, which is largely attributed to limited therapeutic loading technologies and efficiency. As EV cargo has major influence on their functionality, understanding and translating the biology underlying the packaging and transferring of biomolecule cargos (e.g. miRNAs, pathogen antigens, small molecule drugs) into EVs is key in harnessing their therapeutic potential. In this review, through recent insights into EVs' content packaging, we discuss different mechanisms utilized by EVs during cargo packaging, and how one might therapeutically exploit this process. Apart from the well-characterized EVs like exosomes and microvesicles, we also cover the less-studied and other EV subtypes like apoptotic bodies, large oncosomes, bacterial outer membrane vesicles, and migrasomes to highlight therapeutically-diverse opportunities of EV armoury.
细胞外囊泡 (EVs) 是细胞在各种(病理)生理条件下释放的膜结合颗粒。EVs 可以传递效应分子,并在受体细胞中引发强烈的反应,使它们成为有吸引力的治疗剂和药物递送平台。与它们巨大的潜力形成鲜明对比的是,只有少数基于 EV 的疗法和药物递送被批准用于临床使用,这主要归因于有限的治疗性装载技术和效率。由于 EV 货物对其功能有重大影响,因此理解和转化将生物分子货物(例如 miRNA、病原体抗原、小分子药物)包装和转移到 EVs 中的生物学基础对于利用其治疗潜力至关重要。在这篇综述中,通过对 EVs 内容包装的最新见解,我们讨论了 EVs 在货物包装过程中使用的不同机制,以及如何在治疗上利用这一过程。除了众所周知的 exosomes 和 microvesicles 外,我们还介绍了研究较少的其他 EV 亚型,如凋亡小体、大 oncrosome、细菌外膜囊泡和迁移体,以突出 EV 武器库的治疗多样性机会。